Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody

• Status: Completed
• Trial end date: 2021-05-18
• Target enrollment: 0
• Participant gender: All

Summary

International, multicenter, long-term, follow-up study that will enroll HLH patients who have received NI-0501 in a previous clinical trial, in the context of the clinical development program for NI-0501

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NovImmune SA; Swedish Orphan Biovitrum
• Collaborators: Seventh Framework Programme; Supported by a grant of the 7th framework programme "FP7" from the European Committee
• Treatments: Antibodies; Antibodies, Monoclonal; Interferon-gamma; Interferons

Criteria

Inclusion Criteria:

• Having received at least one dose of NI-0501.

• Having signed the Informed Consent by the patient or the patient's legal representative(s), as applicable, with the assent of patients who are legally capable of providing it.

Exclusion Criteria:

• None